Korea FilingsFull brief — $39

HYUNDAI PHARMACEUTICAL CO., LTD

현대약품(주) · KOSPI: 004310 · Pharmaceuticals and medicinal chemicals

Key facts

Korean name
현대약품(주)
Market / ticker
KOSPI · 004310
Industry
Pharmaceuticals and medicinal chemicals
Established
1965-07-16
Fiscal year ends
November
Website
www.hyundaipharm.co.kr
DART corp code
00164706
Latest revenue
₩191.8B (FY2025)

Items worth checking

No rule-based items found in the latest annual report or the last 12 months of filings. This is a limited automated check, not a clean bill of health.

Financial summary

KRWFY2023FY2024FY2025
Revenue₩180.8B₩175.7B₩191.8B
Operating income₩6.9B₩181M₩4.2B
Net income₩6.1B−₩575M₩2.5B
Total assets₩154.6B₩156.4B₩163.2B
Total liabilities₩70.0B₩77.3B₩81.1B
Total equity₩84.7B₩79.1B₩82.1B
Share capital₩16.0B₩16.0B₩16.0B

Separate statements · FY2025 operating margin 2.2% · liabilities to equity 99% · Annual report FY2025 (Korean original)

Auditor opinions

PeriodAuditorOpinion
Term 62 (current)삼화회계법인Unqualified
Term 61 (prior)삼화회계법인Unqualified
Term 60 (two years prior)삼화회계법인Unqualified

Largest shareholder history

No change history reported in the latest annual report.

Recent filings

DateFilingOriginal
2026-07-15Fair trade compliance program status (notice)DART
2026-07-15Half-year report (2026.05)DART
2026-06-01Corporate governance reportDART
2026-04-14Quarterly report (2026.02)DART
2026-03-26Material management matterDART
2026-03-04Large shareholding (5%+) reportDART
2026-02-27Material event reportDART
2026-02-27Treasury share disposal results reportDART
2026-02-27Decision to acquire shares of another companyDART
2026-02-27Amended: Material event report — Treasury share disposal decisionDART
2026-02-26Material event report — Treasury share disposal decisionDART
2026-02-24Annual general meeting resultsDART
2026-02-13Annual report (2025.11)DART
2026-02-13Audit report submittedDART
2026-02-09Record date for cash / in-kind dividendDART
2026-02-09Cash / in-kind dividend decisionDART
2026-02-09Notice of shareholders meetingDART
2026-02-09Resolution to convene shareholders meetingDART
2026-02-09Fair trade compliance program status (notice)DART
2026-01-05Revenue or profit structure changed materiallyDART

Showing the 20 most recent of 23 filings. The full brief lists all of them.

Full brief on HYUNDAI PHARMACEUTICAL CO., LTD — $39 Get the full brief

For business customers. EU companies: enter your VAT number at checkout and no VAT is charged (reverse charge).

Other Korean companies in Pharmaceuticals and medicinal chemicals

Data generated 2026-09-16 from OpenDART.

This page summarizes public filings from DART, the official electronic disclosure system of Korea. It is not investment, credit or legal advice. Figures are shown in the currency the company reports in. Titles and labels are machine-translated and may contain errors — always check the linked original filing. Source: OpenDART, Financial Supervisory Service, Korea.